Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Hepatitis C

Free Subscription 10.12.2018 1 J Gen Virol 3 J Viral Hepat 1 Lancet Gastroenterol Hepatol 1 Lancet HIV 5 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

J Gen Virol

1. ZHANG Y, Zou J, Zhao X, Yuan Z, et al
   Hepatitis C virus NS5A inhibitor daclatasvir allosterically impairs NS4B-involved protein-protein interactions within the viral replicase and disrupts the replicase quaternary structure in a replicase assembly surrogate system.
   J Gen Virol. 2018 Dec 5. doi: 10.1099/jgv.0.001180.
   PubMed     Text format     Abstract available
   
   

   
   J Viral Hepat

2. RAUWOLF K, Herbruggen H, Zollner S, Thorer H, et al
   Durable control of Hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic hematopoietic stem cell transplantation.
   J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13046.
   PubMed     Text format     Abstract available
   
   
3. POURMARZI D, Hall L, Hepworth J, Smirnov A, et al
   Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of Hepatitis C Virus infection: a mixed method systematic review.
   J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13045.
   PubMed     Text format     Abstract available
   
   
4. LEE SS, Kim CY, Kim BR, Cha RR, et al
   Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea.
   J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13047.
   PubMed     Text format     Abstract available
   
   

   
   Lancet Gastroenterol Hepatol

5. THE LANCET GASTROENTEROLOGY HE
   Drug pricing: still a barrier to elimination of HCV.
   Lancet Gastroenterol Hepatol. 2018;3:813.
   PubMed     Text format    
   
   

   
   Lancet HIV

6. THE LANCET HIV
   Microelimination could be a big deal for HCV and HIV services.
   Lancet HIV. 2018;5:e605.
   PubMed     Text format    
   
   

   
   PLoS One

7. RAU M, Schmitt J, Berg T, Kremer AE, et al
   Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients.
   PLoS One. 2018;13:e0208225.
   PubMed     Text format     Abstract available
   
   
8. ABADIE R, Goldenberg S, Welch-Lazoritz M, Fisher CB, et al
   Establishing trust in HIV/HCV research among people who inject drugs (PWID): Insights from empirical research.
   PLoS One. 2018;13:e0208410.
   PubMed     Text format     Abstract available
   
   
9. BOUACIDA L, Suin V, Hutse V, Boudewijns M, et al
   Distribution of HCV genotypes in Belgium from 2008 to 2015.
   PLoS One. 2018;13:e0207584.
   PubMed     Text format     Abstract available
   
   
10. JUANBELTZ R, Perez-Garcia A, Aguinaga A, Martinez-Baz I, et al
    Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain.
    PLoS One. 2018;13:e0208554.
    PubMed     Text format     Abstract available
    
    
11. MADDEN A, Hopwood M, Neale J, Treloar C, et al
    Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
    PLoS One. 2018;13:e0207226.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: